Section Arrow
PSTV.NASDAQ
- Plus Therapeutics
(Financial Status)
Quotes are at least 15-min delayed:2025/11/16 02:43 EST
Regular Hours
Last
 0.5115
-0.0116 (-2.22%)
Day High 
0.5283 
Prev. Close
0.5231 
1-M High
0.733 
Volume 
2.46M 
Bid
0.509
Ask
0.5174
Day Low
0.5002 
Open
0.505 
1-M Low
0.486 
Market Cap 
71.89M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 0.54 
20-SMA 0.56 
50-SMA 0.58 
52-W High 2.3099 
52-W Low 0.1634 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.96/-0.16
Enterprise Value
71.92M
Balance Sheet
Book Value Per Share
0.04
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
0.00
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1063+0.0011+1.05%-- 
CYPHCypherpunk Technologies Inc.2.75+0.99+56.25%-- 
IVVDInvivyd2.35+0.58+32.77%-- 
APLTApplied Therapeutics0.2183-0.0517-19.15%-- 
RXRXRecursion Pharmaceuticals4.14-0.19-4.39%-- 
Quotes are at least 15-min delayed:2025/11/16 02:43 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.